Table 1. Statistical analyses of proportions of subtype A and D in the treatment-naive and antiretroviral-resistant populations in Kampala, Uganda.
| Population of tested individuals | Conditions | Subtype A | Subtype D | P-value |
|---|---|---|---|---|
| Treatment naive (2000–2010) | 254 | 138 | ||
| All treatments (2000–2010) | All tests | 484 | 334 | 0.0604 |
| All test with resistance | 365 | 272 | 0.0171 | |
| All tests with resistance to: | ||||
| __NRTIs/NtRTIs | ||||
| ____3TC | 306 | 233 | 0.0136 | |
| ____ABC | 320 | 242 | 0.0147 | |
| ____ZDV | 186 | 175 | 0.0002 | |
| ____D4t | 200 | 177 | 0.0009 | |
| ____ddI | 227 | 195 | 0.0014 | |
| ____FTC | 306 | 233 | 0.0136 | |
| ____TDF | 161 | 160 | 0.0001 | |
| __NNRTIs | ||||
| ____DLV | 318 | 228 | 0.0424 | |
| ____EFV | 335 | 237 | 0.0513 | |
| ____ETR | 279 | 188 | 0.1285 | |
| ____NVP | 338 | 237 | 0.0595 | |
| First-line treatment (2000–2010) | All tests | 245 | 152 | 0.3691 |
| All test with resistance | 198 | 121 | 0.4523 | |
| All tests with resistance to: | ||||
| __NRTIs/NtRTIs | ||||
| ____3TC | 173 | 109 | 0.3594 | |
| ____ABC | 179 | 114 | 0.3200 | |
| ____ZDV | 111 | 81 | 0.1015 | |
| ____D4t | 118 | 82 | 0.1675 | |
| ____ddI | 132 | 91 | 0.1670 | |
| ____FTC | 173 | 109 | 0.3594 | |
| ____TDF | 95 | 66 | 0.1999 | |
| __NNRTIs | ||||
| ____DLV | 177 | 106 | 0.5479 | |
| ____EFV | 185 | 112 | 0.4980 | |
| ____ETR | 155 | 89 | 0.7449 | |
| ____NVP | 186 | 113 | 0.4833 | |
| Salvage therapy (2000–2010) | All tests | 80 | 82 | 0.0007 |
| All test with resistance | 60 | 64 | 0.0011 | |
| All tests with resistance to: | ||||
| __NRTIs/NtRTIs | ||||
| ____3TC | 48 | 55 | 0.0008 | |
| ____ABC | 50 | 57 | 0.0007 | |
| ____ZDV | 30 | 38 | 0.0012 | |
| ____D4t | 29 | 40 | 0.0003 | |
| ____ddI | 34 | 48 | 0.0001 | |
| ____FTC | 48 | 55 | 0.0008 | |
| ____TDF | 26 | 42 | 0.0000 | |
| __NNRTIs | ||||
| ____DLV | 55 | 43 | 0.1116 | |
| ____EFV | 55 | 47 | 0.0432 | |
| ____ETR | 46 | 40 | 0.0495 | |
| ____NVP | 55 | 47 | 0.0432 |
ABC, abacavir; D4T, stavudine; ddI, didanosine; DLV, delaviridine; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine; 3TC, lamivudine.